X
Axovant axes neuroscience drug, focuses on gene therapies
https://pharmaphorum.com/news/axovant-axes-neuroscience-drug-focuses-on-gene-therapies/
Axovant
Axovant CEO David Hung quits after Alzheimer’s drug failure
Last month the biotech Axovant was rocked by the failure of its star drug intepirdine in Alzheimer’s disease – and the fall-out is still being felt, with CEO David Hung deciding to walk out.
Bad week for dementia R&D after Axovant howler and another failed trial
Axovant misreports trial results, Lundbeck Alzheimer’s drug fails
Axovant axes dementia drug after disastrous trial results
Intepirdine seemed to make symptoms worse in Lewy body disease
Alzheimer’s failure bursts Axovant’s bubble
Shares fall off a cliff after intepirdine fails to produce results.
